Starting a career in life sciences means entering a sector where innovation, purpose and impact come together. 💡 At LEAP HR: Life Sciences Europe, Gi Group Holding spoke with Tony Goonan (Gi Group Holding), Silvia Catellani (ProQR Therapeutics) and Julie Copperthwaite about the advice they would give to younger graduates considering a future in this field. Their message is clear: stay open to learning and new experiences, understand the values that guide the organisations you join, and recognise the broader impact that work in life sciences can have on patients, communities and society. For many professionals, contributing to advances that improve and extend lives is what makes this sector truly worth it. 🩵 To explore more insights on the future of talent in life sciences, discover the Life Sciences Global HR Trends Report 2026. 👉 Access the full report here: https://lnkd.in/eWZkZEWc #GiLifeSciences #LifeSciences #HRTrends #Careers #YoungTalent #TalentAttraction

Starting a career in life sciences means entering a sector where innovation, purpose and impact come together. 💡 At LEAP HR: Life Sciences Europe, Gi Group Holding spoke with Tony Goonan (Gi Group Holding), Silvia Catellani (ProQR Therapeutics) and Julie Copperthwaite (OXB) about the advice they would give to younger graduates considering a future in this field. Their message is clear: stay open to learning and new experiences, understand the values that guide the organisations you join, and recognise the broader impact that work in life sciences can have on patients, communities and society. For many professionals, contributing to advances that improve and extend lives is what makes this sector truly worth it. 🩵 To explore more insights on the future of talent in life sciences, discover the Life Sciences Global HR Trends Report 2026. 👉 Access the full report here: https://lnkd.in/eWZkZEWc #GiLifeSciences #LifeSciences #HRTrends #Careers #YoungTalent #TalentAttraction

Talent dynamics in Life Sciences are becoming a key factor in how companies scale, compete and build long-term value. Our latest report, “Inside Life Science Minds 2026 Poland – Salaries and Working Conditions Trends”, provides a detailed view of compensation, benefits, career expectations and talent mobility across the sector, with a special focus on biotech and biopharma, R&D, and BD roles. We are making it available free of charge to our Life Science community. Comment under this post with “Life Science Report” or message us directly (Monika Kozdron-Sikorska or Karolina Jarosinska) to get the copy*. The report brings valuable insights for leadership teams, investors and professionals operating in the sector. 🟢 If you’re not following us yet - now’s a great time to start. *We reserve the right,at our sole discretion and without obligation to provide justification, to withhold delivery of the report where submitted information is incomplete, unverifiable, or reasonably deemed suspicious, including requests containing non-identifiable or fictitious data.

So excited about this upcoming event on 5th May at the Medical Technology Association of Australia (MTAA) office. If you have any pain points around retention and how to keep your people engaged, invested and performing at the highest level, come and talk to us and others in industry about how to measure “employee attachment” in your new employees’ first 90 days with your organisation. The insights we will share will help;   ·       Mitigate the risks of early employee attrition; ·       Achieve a faster ROI through discretionary effort and performance; ·       Accelerate the time it takes for new employees to reach minimum levels of competence and profit contribution/ROI; ·       Make informed decisions about matters relating to talent retention strategy; and ·       Protect the time and expense incurred during the recruitment/training process.   With the average cost of on-boarding a new employee at $100K, strong attachment is the greatest predictor of future performance, discretionary effort and talent retention. Register now via the link here, see you there and get to network with others in medtech and pharma.

Most organisations are still measuring outcomes after the fact. Leading organisations are focusing on what actually drives those outcomes in real time with Attachment and Connection. If you are rethinking how you build, retain, and unlock talent potential, this session will challenge your thinking. I am looking forward to sharing this perspective with Anthony Sork and Elizabeth Pettit. Please join us on Tuesday 5 May at the Medical Technology Association of Australia (MTAA) by clicking on the below registration, seats are limited.

Following a couple of advisory sessions with Clients this month regarding attraction and retention strategies, I felt it a good time to share some thoughts. We are known best for our expertise in securing mid to senior level talent across Europe and the US in HEOR and Access, but we also act as an advisory on specific elements around process, benchmarking and market insights. I was asked to present at the World Evidence, Pricing and Access Congress a few years ago on Talent Attraction and Retention strategies to a group of Pharma and Consulting Leaders, and over the next few weeks will share the insights that I presented in those sessions. For any questions, further advice and insights, reach out to cliff.cox@evisci.com #marketaccess #healtheconomics #heor #RWE #COA

Astellas held an R&D Day at our Japan headquarters for the investment community, sharing how we are strengthening our R&D approach to support long‑term, sustainable VALUE Creation. Our Top Management Team, including Naoki Okamura, President and Chief Executive Officer, and Tadaaki Taniguchi, Chief Research & Development Officer, outlined how we are sharpening strategic focus, reinforcing evidence‑based decision‑making and advancing disciplined execution across our R&D organization, always grounded in science and centered on patients.    The discussions reflected our continued efforts to translate scientific insight into evidence, and evidence into decisions that matter, as we work to address areas of high unmet medical need.    Presentation materials from the R&D Day are available here:  https://lnkd.in/gBvRhKiA    #investors #ChangingTomorrow #AstellasPioneeringScience

It’s been a pleasure to take part in this Partnering With Purpose series with Paddington Life Sciences. I want to extend my thanks to Suki Balendra PhD and Dr Susan Windham-Bannister for their involvement and enthusiasm. In this final video, we reflect on what makes our partnership work so well – from trust and shared purpose to the power of NHS–industry collaboration to deliver meaningful impact. If you haven’t already, I encourage you to watch the first two videos on the Takeda UK and Ireland page, where we explore why strong local clusters and partnerships matter more than ever for patients. ▶️ Watch our conversation below 👇 #PartneringWithPurpose #TakedaUKandIreland

United States Next-Generation Sequencing Market Reflects the Rapid Expansion of Precision Genomics Next-Generation Sequencing (NGS) is transforming the U.S. healthcare and life sciences landscape by enabling faster, more accurate, and more scalable analysis of DNA and RNA. Its applications across precision medicine, oncology, rare disease diagnostics, infectious disease research, and drug discovery continue to expand as genomics becomes more deeply integrated into both research and clinical workflows. According to recent market insights, the United States Next-Generation Sequencing Market is projected to grow from US$ 4.62 billion in 2025 to US$ 20.23 billion by 2034, registering a CAGR of 17.83%. Key factors supporting market growth include: Growing adoption of precision medicine and personalized healthcare Rising demand for genetic diagnostics and cancer profiling Strong public and private investment in genomics and life sciences research Ongoing innovation in sequencing platforms, automation, and bioinformatics The market is also benefiting from broader clinical adoption in hospitals, research institutions, biotech firms, and pharmaceutical companies, reinforcing NGS as a foundational technology in the future of healthcare. For stakeholders in genomics, molecular diagnostics, biotech, pharmaceutical R&D, and healthcare innovation, this is a market with exceptional long-term relevance. 🔗 Full report: https://lnkd.in/dgWebizt #NGS #Genomics #PrecisionMedicine #Biotech #MolecularDiagnostics #HealthcareInnovation #DrugDiscovery #USMarket #LifeSciences #RenubResearch

Scientific progress depends on exceptional people. Quiddity Talent Solutions partners with Biotech and Life Sciences companies to identify, attract, and secure top-tier talent. Because great science needs great teams. 🔗 https://heyor.ca/84VxPZ #STEMTalent #BiotechIndustry #LifeSciencesLeadership #HiringSuccess